John F Rothman Net Worth

The estimated Net Worth of John F Rothman is at least $5.52 Thousand dollars as of 25 October 2007. John Rothman owns over 61,043 units of Ayala Pharmaceuticals stock worth over $5,516 and over the last 19 years John sold ADXS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Rothman ADXS stock SEC Form 4 insiders trading

John has made over 2 trades of the Ayala Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently John bought 61,043 units of ADXS stock worth $10,988 on 25 October 2007.

The largest trade John's ever made was buying 134,732 units of Ayala Pharmaceuticals stock on 15 February 2007 worth over $21,557. On average, John trades about 32,629 units every 42 days since 2006. As of 25 October 2007 John still owns at least 275,775 units of Ayala Pharmaceuticals stock.

You can see the complete history of John Rothman stock trades at the bottom of the page.

What's John Rothman's mailing address?

John's mailing address filed with the SEC is C/O ADVAXIS, INC., TECHNOLOGY CENTER OF NJ, 675 US HWY ONE, NORTH BRUNSWICK, NJ, 08902.

Insiders trading at Ayala Pharmaceuticals

Over the last 20 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C...., and Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.

What does Ayala Pharmaceuticals do?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Complete history of John Rothman stock trades at Ayala Pharmaceuticals

Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kenneth A. Berlin J.D.,
  Pres, Interim CFO, CEO & Director
• Kenneth Berlin,
  President, Chief Executive Officer, Interim Chief Financial Officer, Director
• Andres Gutierrez,
  Chief Medical Officer and Executive Vice President
• Dr. Andres A. Gutierrez M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Roni Appel,
  Independent Director
• David Sidransky,
  Independent Chairman of the Board
• James Patton,
  Independent Non-Executive Vice Chairman of the Board
• Tim McCarthy,
  Investor Relations
• Samir Khleif,
  Independent Director
• Richard Berman,
  Independent Director
• Igor Gitelman CPA, CPA, M.B.A., MBA,
  Chief Accounting Officer & VP of Fin.
• Gregory T. Mayes,,
  Chief Operating Officer
• Robert J. Spiegel,
  Director
• Robert Petit,
  Chief Scientific Officer
• Sara Bonstein,
  Chief Financial Officer
• Thomas J Mckearn,
  Director
• Thomas J Ridge,
  Director
• Murray A Goldberg,
  Director
• Biotech Fund I, L.P.Israel ...,
  
• Capital Partners Gp, L.L.C....,
  
• Anthony A Lombardo,
  Interim CEO
• Molly Henderson,
  Executive Vice President & CFO
• Fredrick D Cobb,
  Vice President Finance
• John F Rothman,
  VP of Clinical Development
• David J Mauro,
  Chief Medical Officer
• Daniel J. O'connor,
  SVP, Legal & Business Dev Off
• Thomas A Moore,
  Director
• Christy Lee French,
  Exec. Dir. of Medical Affairs
• Mark J Rosenblum,
  Chief Financial Officer
• Biotech Fund I, L.P.Israel ...,
  
• Growth Fund Limited Partner...,
  10% owner
• Vered Bisker Leib,
  Director